Q2 FY2026 · ended Jun 30, 2026 · Revenue $5,000, +0.0% YoY · Filed Aug 13, 2026
Skinvisible, Inc. (SKVI) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $5,000 and a net loss of $255,533.
Revenue
$5,000
+0.0% vs year-ago quarter
Net income
$-255,533
+6.9% vs year-ago quarter
Operating cash flow
$2,161
+123.5% vs year-ago quarter
Free cash flow
$1,975
+155.4% vs prior quarter
EPS
$0.05
+179.4% vs prior quarter
Dividend per share
None
Shares outstanding
5.40M
+0.0% vs year-ago quarter
Net cash
—
Operating margin
-2294.9%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SKVI (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Las Vegas, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1085277
- Former names
- SKINVISIBLE INC (until Aug 14, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $5,000 | $5,000 | $5,000 | $5,000 | $5,000 |
| Operating income | -$112,817 | -$125,938 | -$114,169 | -$106,057 | -$136,237 |
| Net income | -$255,533 | -$267,184 | -$258,357 | -$250,245 | -$274,427 |
| Operating cash flow | $2,161 | -$822 | $1,975 | $524 | -$9,189 |
| Free cash flow | — | — | $1,975 | -$3,562 | -$13,276 |
| Total assets | $123,334 | $119,419 | $127,567 | $133,623 | $143,375 |
| Total liabilities | $10.9M | $10.6M | $10.4M | $10.1M | $9.9M |
| Stockholders' equity | -$10.8M | -$10.5M | -$10.3M | -$10.0M | -$9.8M |
| Cash and investments | $3,959 | $1,798 | $2,620 | $645 | $120 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Mar 31, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Nov 13, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | Aug 13, 2025 | Jun 30, 2025 |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
All 391 Skinvisible, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.